Global Human Rabies Immune Globulin (HRIG) Market Size, Share and Trends Analysis Report, By Type (200IU and 500IU), and By Application (Category II Exposure and Category III Exposure) Forecast Period (2022-2028)

The global human rabies immune globulin market is anticipated to grow at a CAGR of 4.9 % during the forecast period (2022-2028). Rabies immune globulin is used in conjunction with the rabies vaccine to prevent rabies infection. It works when antibodies are supplied to the patient’s body to fight the rabies virus. Rabies immune globulin is given to those patients who have been affected to a rabies-infected animal such as through a bite, scrape, or lick. The growing prevalence of rabies infection in the humans is driving growth of the human rabies immune globulin market during the forecast period. According to statistics from the Centers for Disease Control and Prevention (CDC) in 2020, cats, dogs, and a few other types of animals are at risk of acquiring the rabies virus.

A number of studies are being conducted to better understand the link between animal and human transmission of this virus. Furthermore, in October 2020, an article published in Nature magazine, a study titled “Rabies virus-based COVID-19 vaccine CORAVAX induces high levels of neutralizing antibodies against SARS-CoV-2”, which looked at the rapid development of a novel, highly efficient, and safe COVID-19 vaccine using a rabies virus-based vector that has proven to be an effective vaccine against several emerging infectious diseases.

The rise in the number of stray dogs, monkeys, and other rabies-infected animals is a key factor driving the human rabies immune globulin market during the forecast period. According to the World Health Organization, dogs are the leading cause of rabies infection and death in humans, accounting for over 99 % of all rabies cases. Various other factors, such as the development of contamination-free vaccines utilizing innovative culture media, regulatory exams, and government-led public awareness campaigns, continue to encourage marketers to develop new rabies treatments and vaccines. For instance, in March 2022, Sanofi collaborated with IGM Biosciences to develop, manufacture, and market six immunoglobulin M (IgM) antibody agonists, three of which will target cancer while the other three will target immunology/inflammation. Additionally, in April 2020, Grifols, S.A. launched a new 3-mL (900-IU) vial for high-potency HyperRAB (human rabies immune globulin) HyperRAB is the only high-potency rabies immunoglobulin formulation on the market, enables healthcare practitioners greater dosing alternatives, saves storage space, and decreases waste. With over 1 billion international units delivered to over 1 million individuals over 45 years, HyperRAB is the most commonly prescribed rabies immunoglobulin in the US.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- CSL Behring, Grifols, S.A, Sanofi, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Kamada Pharmaceuticals, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Human Rabies Immune Globulin Market Report by Segment

By Type

• 200IU
• 500IU

By Application

• Category II Exposure
• Category III Exposure